Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 2,001 1,612 15 20 2,016 1,632 3,613 35 3,648
2001 2,114 1,761 13 20 2,127 1,781 3,875 33 3,908
2002 2,208 1,822 19 16 2,227 1,837 4,030 35 4,064
                   
 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 245 2,028 22 2,050
2001 211 2,155 20 2,175
2002 197 2,208 19 2,227
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 177 148 66 46
2001 136 154 75 45
         

 

Pediatric AIDS cases reported

Year
2000 0
2001 0
2002 16
   

 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 3,393
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 3,355
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 38

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  AR USA
Men 2,763 680,909
Women 526 146,298
Total 3,289 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 240
New Adult/Adolescent AIDS Cases, Reported in 2001 199
New AIDS Cases in Children <13, Reported through December 2001 0

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  AR USA
Men 154 31,901
Women 45 11,082
Total 199 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 1,837
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 1,822
Estimated Number of Children Living with AIDS at the End of 2002 16
HIV Infection Cases Reported in 2002 197

 

Total Deaths Reported through 2000, due to AIDS = 1,436
HIV Reporting Requirements ?   Yes, Name based reporting.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Providers required to test for HIV unless mother refuses, Providers are required by law to test a pregnant woman as early as possible in her pregnancy or at the time of delivery unless she refuses.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  No, State law does not prohibit syringe exchange programs.
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  No, If taught voluntarily, must stress abstinence.
 
Minors' Right to Consent to HIV/STD Services?  Yes, Physician may notify parents.
 

 

Total Ryan White Funding, FY2000   $4,805,059 FY2002  $5,960,095
 

CDC HIV Prevention Funding for States
 FY2001 $1,801,670

 FY2003   $1,856,701

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation
 

Total ADAP Clients Served, June 2002

  

 

 AR
#		 US
#

  

 316 80,035

 
ADAP Clients Served by Sex, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  Male 255 81 62,034 78
  Female 61 19 16,702 21
  Total 316 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  White 187 59 29,426 37
  Black 122 39 26,245 33
  Hispanic 3 1 19,883 25
  Asian/Pacific Islander 1 0 795 1
  American Indian/Alaskan Native 1 0 795 1
  Other 1 0 795 1
  Total 316 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  <13 years old 0 0 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 221 70 50,105 63
  >44 years old 95 30 27,836 35
  Total 316 100 79,531 100

 
ADAP Clients Served by Income, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  <100% FPL 197 62 38,175 48
  101-200% FPL 101 32 26,245 33
  201-300% FPL 13 4 8,748 11
  301-400% FPL 1 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 316 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  Medicaid 52 17 0 10
  Medicare 93 29 0 6
  Private 30 10 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  AR
$		 US
$
   3,035,193 878,610,754

 
National ADAP Budget by Source, FY 2002  
  AR
$		 AR
%		 US
$		 US
%
  ADAP Earmark 2,586,804 85 619,830,000 71
  Title II Base 0 0 28,886,192 3
  State 330,000 11 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 118,389 4 30,941,439 4
  ADAP Supplemental Grants 0 0 19,170,000 2
  Total 3,035,193 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  AR
$		 US
$
   265,752 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  AR
$		 AR
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 48,317 18 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 33,285 13 7,940,575 12
  Protease Inhibitors 66,826 25 16,433,502 25
  Opportunistic Infections/Other 117,325 44 9,015,329 14
  Total 265,752 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  AR
#		 US
#
   1,073 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  AR
#		 AR
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 267 25 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 131 12 23,933 10
  Protease Inhibitors 189 18 33,813 15
  Opportunistic Infections/Other 486 45 87,746 38
  Total 1,073 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  AR
$		 US
$
   NA 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  AR
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 10 NA
  Other Medications Covered 15 NA
  Total 43 NA

 

ADAP Emergency Cost Containment Measures, February 2003  
  AR
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place No 16 Yes
  Notes